GlassScriptPhysician profile
Steven C Miller
NPI 1003874355
$11,169.23
in general payments reported to CMS, 2019-2025
52 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $557 · 2021: $1,436 · 2022: $1,951 · 2023: $1,789 · 2024: $2,051 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,002.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,635.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,060.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $836.47 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $650.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $601.25 | 2019-2024 | |
| Lilly USA, LLC | $542.40 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $537.58 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.21 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $429.99 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $356.71 | 2019-2025 | |
| Abbott Laboratories | $341.50 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $308.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $293.31 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Corcept Therapeutics | $237.60 | 2023-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $150.72 | 2019-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.